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Abstract
Dengue is the most important arthropod-borne viral disease of public health significance.
Compared with nine reporting countries in the 1950s, today the geographic distribution includes
more than 100 countries worldwide. Many of these had not reported dengue for 20 or more years
and several have no known history of the disease. The World Health Organization estimates that
more than 2.5 billion people are at risk of dengue infection. First recognised in the 1950s, it has
become a leading cause of child mortality in several Asian and South American countries.
This paper reviews the changing epidemiology of the disease, focusing on host and societal factors
and drawing on national and regional journals as well as international publications. It does not
include vaccine and vector issues. We have selected areas where the literature raises challenges to
prevailing views and those that are key for improved service delivery in poor countries.
Shifts in modal age, rural spread, and social and biological determinants of race- and sex-related
susceptibility have major implications for health services. Behavioural risk factors, individual
determinants of outcome and leading indicators of severe illness are poorly understood,
compromising effectiveness of control programmes. Early detection and case management
practices were noted as a critical factor for survival. Inadequacy of sound statistical methods
compromised conclusions on case fatality or disease-specific mortality rates, especially since the
data were often based on hospitalised patients who actively sought care in tertiary centres.
Well-targeted operational research, such as population-based epidemiological studies with clear
operational objectives, is urgently needed to make progress in control and prevention.
Introduction
Dengue is the most important arthropod-borne viral dis-
ease of public health significance. Compared to nine
reporting countries in the 1950s, today the geographic
distribution includes more than 100 countries worldwide.
Many of these had not reported dengue for 20 or more
years and several have no known history of the disease.
The World Health Organization (WHO) estimates that
more than 2.5 billion people are at risk of dengue infec-
tion. Most will have asymptomatic infections. The disease
manifestations range from an influenza-like disease
known as dengue fever (DF) to a severe, sometimes fatal
disease characterised by haemorrhage and shock, known
as dengue hemorrhagic fever/dengue shock syndrome
(DHF/DSS), which is on the increase. Dengue fever and
dengue haemorrhagic fever/dengue shock syndrome are
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caused by the four viral serotypes transmitted from virae-
mic to susceptible humans mainly by bites of Aedes aegypti
and  Aedes albopictus mosquito species. Recovery from
infection by one serotype provides lifelong immunity
against that serotype but confers only partial and transient
protection against subsequent infection by the other
three. First recognised in the 1950s, it has become a lead-
ing cause of child mortality in several Asian and South
American countries.
The average number of DF/DHF cases reported to WHO
per year has risen from 908 between 1950 and 1959 to
514,139 between 1990 and 1999. The real figure is esti-
mated to be closer to 50 million cases a year causing
24,000 deaths. Of an estimated 500,000 cases of DHF/
DSS requiring hospitalisation each year, roughly 5% die
according to WHO statistics. Regional distribution of den-
gue and its serotypes are described elsewhere [1,2]. In
summary, DF/DHF/DSS is an immediate problem in
south and southeast Asia and Central and South America.
Although DF is present in the African region, there are no
cases or outbreaks reported to WHO [3].
Half the world's population lives in countries endemic for
dengue, underscoring the urgency to find solutions for
dengue control. The consequence of simple DF is loss of
workdays for communities dependent on wage labour.
The consequence of severe illness is high mortality rates,
since tertiary level care required for DHF/DSS manage-
ment is beyond the reach of most of the persons at risk.
This paper reviews the changing epidemiology of the dis-
ease, focusing on host and societal factors and drawing on
national and regional journals as well as international
publications. It does not include vaccine and vector issues.
Although each one of the issues taken up below merits an
independent, in-depth treatment, we have selected only
those issues where the literature raises challenges to pre-
vailing views and therefore require further research, par-
ticularly given that most of these issues are key for
improved service delivery in poor countries.
Analysis
Clinical presentation
Dengue infection can cause a spectrum of illness ranging
from mild, undifferentiated fever to illness up to 7 days'
duration with high fever, severe headache, retro-orbital
pain, arthralgia and rash, but rarely causing death. Den-
gue Haemorrhagic Fever (DHF), a deadly complication,
includes haemorrhagic tendencies, thrombocytopenia
and plasma leakage. Dengue Shock Syndrome (DSS)
includes all the above criteria plus circulatory failure,
hypotension for age and low pulse pressure. DHF and DSS
are potentially deadly but patients with early diagnosis
and appropriate therapy can recover with no sequelae.
Case management for DF is symptomatic and supportive.
DHF requires continuous monitoring of vital signs and
urine output. DSS is a medical emergency that requires
intensive care unit hospitalisation [4].
The increase in dengue mortality is considered to be a
reflection of the increase in the proportion of DF patients
who develop DHF/DSS. The pathogenesis of DHF/DSS is
widely considered to be antibody-dependent enhance-
ment in secondary infection with a virus of different sero-
type [5]. Evidence in support of this comes from many
studies including from the Cuban epidemics of 1981 and
1997 [5,6] and a five-year study of Yangon (Myanmar)
[7]. However, absence of a significant association between
secondary infection or co-circulation of different sero-
types and DHF/DSS has also been noted [8,9]. The disease
is widely considered to be associated with secondary
infection and co-circulation of several serotypes.
Alternative or additional factors associated with severe ill-
ness, such as high viraemia titres, have also been sug-
gested [10]. So far, this has been associated with
secondary infection as demonstrated by Vaughn et al., and
Libraty et al. [11,12]. On the other hand, one expression
of higher viral virulence could be higher viraemia leading
to greater severity, but this has not not yet been demon-
strated (Guzmán, 2003 personal communication).
Viral virulence [13], immunological responses and
increased pathogenicity of specific serotypes [14] have
been implicated as critical for the appearance of DHF. This
has been found for the three serotypes DEN1, [13] DEN 2
[15] and DEN 3 [8,10,16,17], but so far not for DEN 4
[18].
The evidence from different studies also shows that the
pathogenesis of DHF/DSS may be multi-factorial and
understanding remains incomplete.
Epidemiological changes
Demographic, economic, behavioural and social factors
are often keys for effective communicable disease control
and underpin successful public health programmes.
Despite promising indications in the literature, these fac-
tors have remained poorly understood in the case of den-
gue. Furthermore, recent field evidence raises some
questions regarding widely accepted characteristics of
dengue that need review and confirmation.
Shift in modal age
DF is typically acknowledged to be a childhood disease
and is an important cause of paediatric hospitalisation in
southeast Asia. There is, however, evidence of increasing
incidence of DHF among older age groups. Since the early
1980s, several studies in both Latin America and south-Emerging Themes in Epidemiology 2005, 2:1 http://www.ete-online.com/content/2/1/1
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east Asia have reported a higher association of DHF with
older ages. The earliest studies were by Guzmán (1981) in
Cuba and Rigau-Pérez in Puerto Rico [6,19]. Later on sim-
ilar observations were noted in Nicaragua and Brazil. In
some southeast Asian countries where dengue has been
epidemic for several years, this age shift is clearly
observed, indicating an epidemiological change in den-
gue infection in those locations [20-22].
Three studies in Asia using surveillance data report
increasing age of infected patients. In Singapore, surveil-
lance data showed a shift in peak dengue mortality from
paediatric ages (1973–1977) to adults in 1982, since
which year more than 50% of the deaths occurred in
patients older than 15 years. From 1990–96, the highest
age-specific morbidity rates were in the 15 to 34 year age
groups [23]. In Indonesia, surveillance data from 1975 to
1984 showed an increase in incidence rates among young
adults in Jakarta as well as in the provincial areas [24].
Adults have accounted for proportions as high 82% of all
cases in the hospital-based surveillance study during the
2000 epidemic of dengue in Bangladesh [25]; the highest
proportion of cases occurred in the 18 to 33 year age
group. All deaths in the Bangladesh outbreak in 2000
were in persons older than 5 years. In Puerto Rico, surveil-
lance data analysis showed the highest incidence rate
(11.8/1000) in the 10–19 year age group during an out-
break in 1994 and 1995 [26].
Hospital-based studies have similarly reported increasing
infection rates among adults, mentioning that it is con-
trary to the popular belief that dengue is a paediatric dis-
ease [27,28]. The trend for increased incidence among
young adults has important implications for control and
prevention. Whether these are real increases (based on
population distributions), increases in the proportion of
DHF/DSS (and, hence, the proportion hospitalised) but
not DF, or the result of improved classification and diag-
nosis needs clarification. Comparative incidence and case
fatality ratios (CFRs) of severe illness in adults and chil-
dren and the economic implications are discussed later.
Racial predisposition
Race-related susceptibility to dengue has been observed in
a few studies and merits further investigation. In a retro-
spective seroepidemiologic study Guzmán reported that
blacks and whites were equally infected with DEN-1 and
DEN-2 viruses during the Cuban epidemics of 1977 and
1981, while severe dengue disease was observed less fre-
quently in dengue-infected black persons than whites
[5,6].
A study in Haiti observed that despite virologic pre-condi-
tions hypothesised to be precursors for DHF (i.e. the evi-
dence of previous infection by DEN virus types 1, 2 and
4), local children did not develop severe illness [29]. The
authors concluded that this finding provides further evi-
dence of a dengue-resistant genotype in black popula-
tions. In 1998 the Los Angeles County vital registration
system reported DF/DHF incidence, but only among His-
panic and white ethnic groups (0.1 and 0.07/100,000)
[30].
Genetic polymorphism in cytokine profiles and coagula-
tion proteins has been proposed as a factor protecting per-
sons of African origin [31]. Evidence for this hypothesis
has been found in meningococcal disease, in which a
genetic polymorphism in the gene encoding an essential
protein involved in coagulation is a predictor for develop-
ing severe disease with lethal outcome.
In Asia, two studies report racial differences in disease
incidence. A 15-year study of the epidemiology of dengue
reports a significantly higher incidence of DHF among
Chinese compared to Malaysian males [32]. This finding
was supported by a six-year surveillance data study in Sin-
gapore, which found the race-specific morbidity rate
among the Chinese to be three times that of the Malays
and 1.7 times that of Indians [23]. Although none of the
above constitutes convincing evidence for the hypotheses,
they highlight a useful area for better understanding of
dengue pathogenesis and health service planning.
Sex differences
Understanding male-female differences in infection rates
and severity of disease is important for public health con-
trol programmes. A few hospital-based studies and sur-
veillance data show a male-female difference in infection
rates and in severity of disease. Three independent studies
from epidemics in India and Singapore found nearly twice
the number of male patients compared to females (Luc-
know and Singapore both report male to female ratios of
1.9:1 and Delhi 1:0.57) [33-35]. In his hospital-based
study during the 1996 epidemic in Delhi, Wali reported
an even higher ratio of 2.5:1 [27]. Another study during
the same epidemic found a male to female ratio of 1:0.25
cases for DSS. However, of the three deaths in this sample,
two were female [35]. Surveillance data from Malaysia
revealed a male preponderance among Indian and Malay
patients (1.5:1), but the ratio was almost equal for those
of Chinese origin [32]. The Ministry of Health, Bangla-
desh reported a hospital patient DF/DHF male to female
ratio of 1.5:1 during an outbreak in Chittagong in 1997
[36], although a later study of DHF only during the 2000
outbreak found no differences between sexes [37]. With
the exception of the study by Shekhar, all the others were
hospital-based and may represent those who sought care
rather than the infected population [27].Emerging Themes in Epidemiology 2005, 2:1 http://www.ete-online.com/content/2/1/1
Page 4 of 10
(page number not for citation purposes)
Studies in South America generally report that both sexes
are equally affected [26,38] although a male to female
ratio of 0.65:1 was described as "typical" for dengue [9].
Kaplan, in a rare study testing for significance, found a
higher proportion of women in all of his four Mexican
samples (p < 0.001) [39].
Of significance are two studies in Asia by Kabra and Shek-
har where severe illness and CFR were consistently higher
among females despite higher incidence in males [32,40].
Halstead [41] had pointed out as early as 1970 that males
predominate among those with milder disease but
females account for more severe illness. He suggested that
either immune responses in females are more competent
than in males, resulting in greater production of
cytokines, or the capillary bed of females is prone to
increased permeability. Kaplan in Mexico suggests that an
incidence bias in favour of females is related to the timing
of the survey interviews, while Goh puts forward that low
incidence among women occurs because they stay at
home and are less exposed to infection [39,42].
No studies suggest gender bias in home care and male
preferences in health care seeking, still prevalent in many
Asian and other traditional societies. It is widely recog-
nised that in many of the Asian communities, lower dis-
ease incidence in women may be a statistical artefact
related to lower reporting and care-seeking for women
from traditional practitioners who do not report to public
surveillance systems. By the same token, women are less
likely to be taken for care at a hospital when ill or are
taken at late stages of disease, when no other options are
available. Determining sex differences, both in infection
and severity of disease, requires well-designed and tar-
geted studies to capture both biological and social factors
that drive disease patterns in a community.
Rural spread
Historically, DF/DHF has been reported as occurring pre-
dominantly among urban populations where density of
dwellings and short flying distance of the vector create the
right conditions for transmission. However, the literature
shows that dengue transmission and, in some cases, out-
breaks occur in rural settings in both Asia and Latin Amer-
ica. In the WHO Western Pacific region, WHO has
confirmed that disease spread into rural areas from where
it had not been reported previously [20].
Rural epidemics occurred as early as 1976 in Indonesia,
and in 1994 the outbreak in Laos began in a remote, rural
district of Nasaithong [43,44]. Today, Thailand has an
incidence rate that is higher in rural (102.2 per 100,000)
than urban areas (95.4 per 100,000) [28]. Similarly, in
India, entomological investigation showed a widespread
distribution of Aedes aegypti, both in rural and urban areas
during an outbreak in Gujarat in 1988 and 1989 [45].
Increase in DF/DHF among rural populations is also
observed in Central and South America and identical rates
in both populations are reported [9]. Among jungle
dwellers in Peru, antibody prevalence up to 67% com-
pared to 66% among the urban population have been
found [46].
In industrialised settings, the Centers for Disease Control
and Prevention (CDC) reported an outbreak of DF among
residents of the rural towns of Hana and Nahiku in
Hawaii in 2001. The outbreak was historically unusual
because infection occurred among residents who have no
history of recent travel and the Aedes aegypti mosquito has
not been seen in Hawaii since it was supposedly eradi-
cated by pesticide spraying in 1943 [47].
Increased transport contact, mobility and spread of peri-
urbanisation have been the most frequently cited reasons
for spread of dengue to rural areas [48]. While some rural
incidence linked to travel contact with urban areas is con-
ceivable, outbreaks and infection rates equal to those in
urban areas warrant further investigation. Improved
reporting could also be a factor, but it would be less likely
in areas such as Hawaii, USA. Standard epidemiological
techniques such as spatial studies of cases and careful
patient histories could shed further light into transmis-
sion patterns in rural populations. Health service struc-
tures and utilisation patterns differ substantially between
urban and rural areas in many tropical countries and con-
textually appropriate strategies will be required for effec-
tive impact.
Seasonality and climate variability
The incidence and, in particular, epidemics of dengue
have been commonly associated with the rainy season,
and the El Niño phenomenon has been incriminated in
the increases of certain vector-borne diseases, including
dengue [49,50].
Despite the number of studies, convincing data or models
supporting these hypotheses are scarce. The relationship
between temperature, rainfall and vector-borne disease
are increasingly seen as oversimplifications. A study mod-
elling DF transmission and seasonal temperature on data
from Puerto Rico from 1988 to 1992 revealed weak rela-
tionships between monthly mean temperature and inci-
dence of DF [51]. The study concluded that factors related
to history of herd immunity, introduction of new serotype
or demographic transitions influence transmission.
More recently, long-term meteorological trends were stud-
ied in four high-altitude sites in East Africa, where
increases in malaria have been reported in the past two
decades [52]. They did not observe any significant changeEmerging Themes in Epidemiology 2005, 2:1 http://www.ete-online.com/content/2/1/1
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in temperature, rainfall, vapour pressure and the number
of months suitable for P. falciparum transmission in the
past century or during the period of reported malaria
resurgence. Others have questioned models linking global
temperatures and disease incidence, stating that, histori-
cally, climate has rarely been the principal determinant of
vector-borne disease prevalence. Neither does the litera-
ture provide an adequate evidence base establishing the
impact of climate change on vector-borne disease [53,54].
The "bandwagon" of El Niño [55] and dengue incidence
is now placed under scrutiny and further research will
have to be done before climate variations can be nailed
down as a culprit.
Health systems issues
Socio-economic context
Social and economic factors play an essential role in the
incidence and prevalence of DF and DHF. Air condition-
ing, screens and safe water supplies in wealthier countries
help prevention and better health services reduce or elim-
inate mortality from DHF. Unplanned urbanisation and
inadequate resources for vector control are factors that
promote transmission and are characteristic of poor rather
than richer countries. Reiter et al. (2003) studied dengue
transmission on the Mexico-USA border and found higher
rates in the Mexican city compared to the American one
[56].
However, some anomalies persist despite the rich/poor
divide in disease incidence. Despite energetic control pro-
grams in the wealthier endemic countries of southeast
Asia such as Singapore, Malaysia and parts of China (eg.
Hong Kong), dengue continues to be a problem. Malaysia
reports some of the highest numbers of cases during epi-
demics compared to other countries in the region. In
some of these cases, particular traditional practices, such
as rainwater storage on roofs, expose them to higher risk.
The major epidemic in Puerto Rico in 1977 serves as a
reminder that advanced public health capacities and eco-
nomic development may not guarantee protection against
massive epidemics [9]. Despite high quality of health serv-
ices and richer circumstances, complacency in endemic
countries may lead to increased rates without continued
vigilance.
On an individual level, evidence points to greater suscep-
tibility among well-nourished or middle-class communi-
ties rather than malnourished and poorer patients
commonly associated with other tropical diseases.
A case-control study of serologically-confirmed DHF
patients, other infectious diseases patients and healthy
children in the Children's Hospital in Bangkok showed
that malnutrition amongst DHF patients was significantly
lower [57]. In India, a hospital-based study found no
association between nutritional status and severity of ill-
ness [40].
Middle classes have been specifically noted as the propor-
tionally predominant group during the epidemic in
Dhaka Bangladesh [25] and upper social classes had sta-
tistically higher sero-infection rates in Fortaleza and San
Luis epidemics in Brazil [38]. Confounding factors for the
preponderance of DF/DHF among the upper classes or
well-nourished dengue patients were not discussed in any
of these studies.
Few studies specifically measure and test socio-economic
determinants of exposure at community levels. Heukel-
bach in Fortaleza, Brazil did examine socio-economic var-
iables but their study did not show an association with DF
[58]. Since all 34 cases selected were from a shanty town
(favela), a lack of heterogeneity may have been a factor for
this result rather than a real absence of difference. In Tai-
wan, Ko, also in a case-control study, observed that
patients who lived near markets and/or open sewers or
ditches had a risk of contracting disease 1.8 times higher
than those who did not [59]. Since housing near sewers
and ditches is likely to comprise poorer families, the anal-
ysis should have tested for house site while controlling for
use of screens, which were significantly associated with
incidence.
Costs
On a macro level, the impact of dengue on the economy
is likely to be increasingly similar to that of malaria. Prev-
alent in communities characterised by subsistence or daily
wage labour, a week's illness can be catastrophic for poor
families. As a primarily paediatric disease in the past, the
active labour force or the family wage earners were less
affected. Now, as the modal age of illness and incidence
increases, losses in productivity and earning capacity may
be expected. The economic lesson from malaria was learnt
late and when the resurgence was already in full swing.
Dengue fever risks the same fate.
With regard to costs of care, few economic studies exist
and most estimate economic loss to range in millions.
Von Allmen et al. undertook a cost analysis of the epi-
demic of DF/DHF in Puerto Rico in 1977 using upper and
lower limits of incidence [60]. They estimated the direct
costs (medical care and epidemic control measures) to
range between US$2.4 and $4.7 million and indirect costs
(lost production of patients and parents of children)
between US$6 and $15 million. Another economic study,
still in Puerto Rico, assessed the loss in terms of DALYs
due to dengue [61]. At 658 DALYs per year per million
population, the study concluded that, in terms of its mag-Emerging Themes in Epidemiology 2005, 2:1 http://www.ete-online.com/content/2/1/1
Page 6 of 10
(page number not for citation purposes)
nitude, DF ranks with TB, STDs (including HIV), child-
hood diseases or malaria.
On a micro level, a detailed study on costs of care in 3 hos-
pitals in Bangkok estimated direct adult patient costs at
US$67. Including opportunity costs, this figure increased
to US$161.49. The net hospital cost for each DHF patient
was US$54.60 and the public sector cost of prevention
and control of the outbreak was US$4.87 million. The
total expenditure for DHF in 1994 was estimated to be at
least US$12.56 million, of which 45% was borne by the
patients [62].
These figures are reminders that most of the countries sub-
ject to DF/DHF cannot realistically afford a US$5 million
prevention and control budget for a single disease and
that the monthly income of many families in these coun-
tries is less than the direct cost of US$70 a month.
Knowledge, attitude and practice (KAP)
Much needs to be done in finding effective strategies for
behaviour change. Since mothers are the first-line care-
givers, this aspect is key, particularly for childhood dis-
eases. KAP studies are rare and therefore little is known
regarding knowledge and attitude of the exposed popula-
tion towards dengue. However, the little that is known is
encouraging.
Straightforward community education to reduce breeding
sites for mosquitoes performed better than chemical
spraying in a controlled experiment in Mexico [63]. How-
ever, housewives, the unemployed and the elderly had sig-
nificantly lower levels of knowledge of the disease
compared to students and persons of younger ages (odds
ratio (OR) = 0.44, 95% confidence interval (CI): 0.31–
0.64). Other KAP studies have found that radio and tele-
vision are very effective channels for knowledge dissemi-
nation. Nevertheless, these same studies found that while
communities can score well in knowledge of the disease,
they perform less well in attitude and practice, indicating
that behaviour change is one area to target in social mobi-
lisation programmes [64-67].
Treatment-seeking behaviour and lay symptom assess-
ment is the first step in the chain to early diagnosis and
was found to have an impact on duration of illness in
Thailand [68]. In that context, it is discouraging to note
that 45% of individuals in a population-based survey
(23,970 households) in the urban municipality of Vien-
tiane did not know what action to take when their chil-
dren are diagnosed with dengue or what they should do
for prevention [44].
Finally, reducing mortality from DHF and strengthening
its control and prevention clearly cannot be done by the
population alone. In most circumstances, these are poor
populations with other pressing agendas. The programme
requires public sector leadership with strong intersectoral
collaboration. The WHO has made important progress to
determine ways and mechanisms through which to
achieve collaboration between sectors and state policy
directions for control.
Trends in case fatality rates
Two aspects present themselves for useful discussion in
this area. One relates to wide variations in CFRs between
countries, sub-national units and hospitals under similar
virological conditions. The other relates to differential
risks of severe illness and mortality between children and
adults.
The global case-fatality rate (CFR) for DHF/DSS has been
declining in most of the endemic countries according to
government statistics. The overall CFR in the southeast
Asia region is now less than 1% [20]. However, disaggre-
gated data reveal a different picture. Rates vary signifi-
cantly between countries, provinces and hospitals,
pointing to a more complex situation.
From 1995–2000, the CFR in the countries of WHO West-
ern Pacific Region ranged from 0.06% in Singapore and
0.17% in Malaysia to 3.4% in Cambodia. Hong Kong
reported no deaths [69]. In Vietnam, province-based 1998
data for DHF show CFR ranging from nearly 13% in Ha
Tinh to 0.5% in Quang Tri [70]. Although the four prov-
inces with the highest CFR were at some distance from Ho
Chi Minh City or Hanoi, the four of the lowest were not
particularly closer to these centres of tertiary care. In Laos,
on the other hand, CFR for DHF during 1998 reached a
high of 9.7% in Champassak province compared to 1.4%
in Municipality of the capital city, Vientiane [44]. Wide
variation in CFRs ranging from 0.1% to 5%, was also
noted between the first administrative divisions in the
Philippines [71].
During the 1998 epidemic in Cambodia the CFR in Kan-
tha Bopha, a private, charitable hospital, was substantially
lower (1.96%) than the national average (2.91%) [70].
Inter-district and inter-hospital variation is generally
indicative of quality of care. Availability of medical sup-
plies, equipment and economic status of patients can
explain some differences but analyses to distinguish
between the performances of provinces and countries in
comparable settings would be useful for designing more
effective disease control.
Secondly, studies have postulated higher risk of DF/DHF
morbidity and mortality among children compared to
adults [15]. Recently, increasing reports of severe illness
among adults and in some cases higher CFRs (e.g. age-spe-Emerging Themes in Epidemiology 2005, 2:1 http://www.ete-online.com/content/2/1/1
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cific CFRs from San Lazaro hospital over one year were
3.8% for 35–39 year olds, 8% for over 45s compared with
2% and 2.6% for 0–4 and 5–9 year age groups) merit
closer looks at determinants of adult mortality [37,71,72].
Case management and early detection
In addition to vector control, widely recognised as a pre-
ventive strategy of choice, key health sector response for
reduction of mortality and morbidity lies primarily in two
areas: early detection (including care-seeking behaviour
change and better surveillance) and improved case man-
agement of patients. Mortality in excess of 1% may be
considered the consequence of inadequate care, late diag-
nosis and delayed hospitalisation.
A hospital-based study during the dengue outbreak in
Delhi revealed that mortality could be very low in patients
who came early to the hospital [73]. Late presentation was
also strongly associated with increased mortality in chil-
dren with DHF in the Philippines [74].
The short interval between onset of haemorrhage and
death, especially in young children, makes rapid medical
intervention for DHF/DSS a critical factor for survival. For
most communities at highest risk of disease, intensive care
facilities are only available at distant capitals requiring
motorised transport, usually beyond the reach of many.
Early diagnosis and leading indicators for DHF/DSS can
ensure the availability of travel time to transfer the patient
for effective treatment. Case-control studies have shown
that low-normal hematocrit count at time of shock is a sig-
nificant risk factor for haemorrhage [75] and potential
predictors for clinical outcome, such as decrease in total
plasma cholesterol, and high- and low-density lipopro-
tein, were associated with the severest cases [76].
However, research into predictive factors for severe illness
is neither abundant nor conclusive. Moreover, as Van
Gorp concludes, low capacity and lack of resources at sec-
ondary levels of health services limit the operational use
of many of these findings [76].
At this time, the WHO classification of dengue diseases is
often not feasible in many countries because of lack of
trained health professionals, inadequate laboratories, and
radiological support. Neither are facilities to detect DHF
by using hematocrit and plasma leakage signs readily
available in many tropical countries. As successful treat-
ment of dengue depends on symptom recognition and
careful fluid management, a simpler dengue disease clas-
sification scheme, realistic in poor, provincial conditions
and better training of district-level personnel is needed.
A few creative approaches to primary health care to
improve quality of care and case management at primary
health care levels have been reported in the literature. For
example, encouraging results have been found in Vietnam
where they reduced dengue mortality rates by 64%
through innovative primary healthcare concepts, includ-
ing paediatric priority training units for medical staff,
health education for patient carers and promotion of out-
patient treatment to avoid unnecessary admissions [77].
Reduction of CFRs from 10–15% (40% in some areas) in
the early 1950s to less than 0.5% today in east Asian refer-
ral hospitals have been attributed to better training of the
hospital staff [78].
The effect of strengthened health systems is recognised by
public health authorities including WHO but is missing
operational research and policies to put them into effect.
Surveillance and reporting
Unreliable statistics are an extremely serious weakness
from many perspectives. Estimates of DHF/DSS CFR from
surveillance data are consistently lower than those from
single sample study data suggesting under-reporting or
misclassification of deaths. Inadequate knowledge of case
definitions among district health personnel compromise
complete reporting even within the public health service
system. Inappropriate denominators further add to the
confusion in estimating prevalence and incidences.
Reporting deviations can lead to seriously misleading
CFRs in countries where reliable estimates are urgently
needed for effective resource programming. In Laos, for
instance, 8197 DHF cases and 24 deaths were registered
by the WHO in 1996, compared to 2563 cases and 23
deaths registered by the Institute of Malariology, Parasi-
tology and Entomology (IMPE) for a CFR of that is 3 times
higher than WHO statistics [22], Most national surveil-
lance data rely only on public sector institution reporting.
An evaluation of the dengue reporting system in Bandung,
Indonesia (covering private and public hospitals) found
that only 31% of hospitalised DHF/DSS cases were
reported to the Municipal Health Authorities [79]. In
Puerto Rico, a hospital record review revealed a ratio of
3:1 total DHF cases compared to those detected by surveil-
lance [80]. More alarmingly, in Texas, USA, an assessment
of underdiagnosis of dengue was undertaken motivated
by an outbreak in a town across the border in Mexico. A
review of medical records between 23 July and 20 August
1999 found that 50% of suspected cases had undiagnosed
dengue infection. [81].
Based on the above studies, a conservative estimate would
be that a third of the total cases are captured by surveil-
lance systems, indicating that the global incidence rate
could be around 1.5 million cases of DHF on an average
year rather than the 0.5 million estimated by WHO.Emerging Themes in Epidemiology 2005, 2:1 http://www.ete-online.com/content/2/1/1
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While complete surveillance data may be an unrealistic
option in many the affected countries, sentinel surveil-
lance and sample surveys using reliable methodologies
could be undertaken to provide more accurate estimates
of the disease burden and fill in the gaps. Occasional sam-
ple surveys of the private sector could help better estimate
the bias in disease burden.
Conclusion
On 18 May 2002, the WHO General Assembly confirmed
dengue fever as a matter of international public health pri-
ority through a resolution to strengthen dengue control
and research.
Today, changing characteristics of the disease deserve seri-
ous research attention. Shifts in modal age, rural spread,
social and biological determinants of race- and sex-related
susceptibility have major implications for health service
planning and control strategies. Behavioural risk factors,
individual determinants of outcome and leading indica-
tors of severe illness are poorly understood, compromis-
ing the effectiveness of control programmes. Early
detection and case management practices have been
noted as a critical factor for survival. Yet well-targeted
operational research in these areas is rare. Population-
based epidemiological studies with clear operational
objectives should be launched as concerted efforts at
regional levels.
A major weakness is the inadequacy of sound statistical
methods in some of the reviewed studies. Samples are
exceedingly small in many cases, selection methods are
often inadequately described or are self selecting, tests of
significance are frequently not undertaken or not reported
and denominators are not clearly described. Conclusions
therefore do not have the full benefit of objective statisti-
cal analyses, reducing the scientific strength of the results.
Furthermore, conclusions regarding case fatality or dis-
ease-specific mortality rates are hard to draw since they are
frequently based on hospitalised patients who had
actively sought care in tertiary centres. However, a system-
atic approach and a clear international research agenda
can quickly bring forward the frontiers of knowledge. Bet-
ter understanding of the above will not only feed into
operational policy for dengue control, but also provide
fertile terrain for vaccine application strategies in the
future.
Today, dengue control and prevention requires thinking
outside the tropical disease box. Many of the affected
countries are some of the poorest. Approaches that are
realistic for their infrastructure need to be urgently devel-
oped.
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